Compare · CNSP vs NVO
CNSP vs NVO
Side-by-side comparison of CNS Pharmaceuticals Inc. (CNSP) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNSP and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 25419.2x CNSP ($8.5M).
- Over the past year, CNSP is down 8.9% and NVO is down 12.1% - CNSP leads by 3.2 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 7 for CNSP).
- NVO has more recent analyst coverage (25 ratings vs 0 for CNSP).
- Company
- CNS Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $5.76+5.69%
- $48.65+3.65%
- Market cap
- $8.5M
- $215.46B
- 1M return
- -0.69%
- -2.08%
- 1Y return
- -8.86%
- -12.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 7
- 9
- Recent ratings
- 0
- 25
CNS Pharmaceuticals Inc.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CNSP
- SEC Form DEFA14A filed by CNS Pharmaceuticals Inc.
- SEC Form DEF 14A filed by CNS Pharmaceuticals Inc.
- Director Fisher Michal bought $10,000 worth of shares (2,000 units at $5.00) (SEC Form 4)
- CEO and President Levin Rami decreased direct ownership by 50% to 4,750 units (SEC Form 4)
- SEC Form 3 filed by new insider Fisher Michal
- CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation
- SEC Form 10-Q filed by CNS Pharmaceuticals Inc.
- CNS Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment
- SEC Form EFFECT filed by CNS Pharmaceuticals Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S